אוורל 25 ישראל - עברית - Ministry of Health

אוורל 25

j-c health care ltd - estradiol as hemihydrate 1.6 mg - patches - estradiol - deficiency symptoms by absence of estrogen after the menopause or after surgical removal of the ovarians. they comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis. in women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.

אוורל 75 ישראל - עברית - Ministry of Health

אוורל 75

j-c health care ltd - estradiol as hemihydrate 4.8 mg - patches - estradiol - deficiency symptoms by absence of estrogen after the menopause or after surgical removal of the ovarians. they comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis.in women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.

אוורל 100 ישראל - עברית - Ministry of Health

אוורל 100

j-c health care ltd - estradiol as hemihydrate 6.4 mg - patches - estradiol - deficiency symptoms by absence of estrogen after the menopause or after surgical removal of the ovarians. they comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis. in women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.

גינרה ישראל - עברית - Ministry of Health

גינרה

bayer israel ltd - ethinylestradiol; gestodene - טבליות מצופות - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - hormonal contraception.

נוברינג ישראל - עברית - Ministry of Health

נוברינג

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - טבעת וגינלית - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

פלורט ישראל - עברית - Ministry of Health

פלורט

dexcel ltd, israel - ethinylestradiol; gestodene - טבליה - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - contraceptive.

פליים ישראל - עברית - Ministry of Health

פליים

dexcel ltd, israel - ethinylestradiol; gestodene - טבליה - ethinylestradiol 0.02 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - contraceptive.

אסטרופם 2 מג ישראל - עברית - Ministry of Health

אסטרופם 2 מג

novo nordisk ltd., israel - estradiol as hemihydrate - טבליות מצופות פילם - estradiol as hemihydrate 2 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.

אסטרוג'ל ישראל - עברית - Ministry of Health

אסטרוג'ל

cts ltd - estradiol - ג'ל - estradiol 0.06 %w/w - estradiol - estradiol - hormonal replacement therapy for the treatment of symptoms associated with estrogen deficiency in menopausal women. prevention of postmenopausal osteoporosis in women with an increased risk for osteoporotic fractures and presenting intolerace or a contraindication to others treatments indicated in the prevention of osteoporosis.

אסטרופם 1 מג ישראל - עברית - Ministry of Health

אסטרופם 1 מג

novo nordisk ltd., israel - estradiol as hemihydrate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.